LRRK2 and Parkinson disease: The observed differences in cytokine profiles in LRRK2 KO mice after Mtb infection highlight that LRRK2 controls specific inflammatory pathways which need to be considered when evaluating the long‐term use of LRRK2 kinase inhibitors in PD patients.